bioRxivMolecular BiologyPreprint
DAB2 as a biomarker and mechanistic link between lipid dysregulation and disease progression in LGMD R2
Céline BrugeiD, Nathalie BourgiD, Emilie PellieriD, Quentin MiagouxiD, Manon Benabidès, Noëlla GrossiiD, Margot JarrigeiD, Hélène PolvècheiD, Valeria AgostiniiD, Anthony Brureau, Stéphane VassilopoulosiD, Teresinha EvangelistaiD, Gorka Fernández‐EulateiD, Tanya StojkoviciD, Isabelle RichardiD, Xavier NissaniD
Abstract
Limb-girdle muscular dystrophy R2 (LGMD R2) is an autosomal recessive disorder caused by dysferlin deficiency, leading to progressive muscle weakness and wasting. Despite advances in understanding the mechanisms linking dysferlin loss to membrane fragility and muscle degeneration, the lack of robust clinical biomarkers has limited disease monitoring and therapeutic evaluation. Here, we identify Disabled-2 (DAB2) as a molecular and clinical biomarker for LGMD R2. Transcriptomic profiling revealed a significant upregulation of DAB2 in induced pluripotent stem cell (iPSC)-derived myotubes from patients with LGMD R2. Its expression correlated with disease severity in muscle biopsies from a cohort of 14 dysferlin-deficient individuals and in dysferlin knockout Bla/J mice, where levels increased with disease progression. Crucially, we demonstrate that DAB2 upregulation in muscle is normalized following treatment with AAV gene therapy expressing full-length dysferlin, positioning DAB2 as a dynamic biomarker for both disease monitoring and therapeutic response. Based on the role of DAB2 in lipid trafficking and the reported pathological lipid accumulation in LGMD R2, we then investigated its contribution to disease-associated lipid dysregulation. Consistent with this hypothesis, we show that high DAB2 levels paralleled lipid deposition in affected patients, iPSC-derived myotubes and mouse muscles, while siRNA- mediated DAB2 knockdown reduced lipid accumulation in LGMD R2 myotubes. Together, our findings establish DAB2 as a mechanistic link between disease severity and lipid dysregulation, and highlight its potential as a key prognostic marker, opening new avenues for precision medicine approaches in LGMD R2 and other related muscular dystrophies. Graphical abstract O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=133 SRC="FIGDIR/small/675589v1_ufig1.gif" ALT="Figure 1"> View larger version (40K): org.highwire.dtl.DTLVardef@152c1f1org.highwire.dtl.DTLVardef@3af57eorg.highwire.dtl.DTLVardef@cb4630org.highwire.dtl.DTLVardef@16d384b_HPS_FORMAT_FIGEXP M_FIG C_FIG
- organism: mouse
- organism: human
- assay: bulk RNA-seq
- research focus: differential expression
- research focus: gene regulatory network inference
- research focus: drug response / drug discovery
- approach: statistical model
- approach: experimental assay
- Citations
- 0
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Circulating miR-4532 is associated with loss of ambulation in dysferlinopathy
Tajveer Singh Grewal, Zsuzsanna Hollander, … Amrit Singh·bioRxiv·Jan 6, 2026
- Identification of bazedoxifene for the treatment of LGMD R2 by high throughput screening.
Céline Bruge, Nathalie Bourg, … Xavier Nissan·British Journal of PharmacologyPeer-reviewed·Mar 19, 2025
- Muscle transcriptome profiling reveals novel molecular pathways and biomarkers in laminin-α2 deficient patients
Veronica Pini, Francesco Catapano, … Francesco Muntoni A·Acta Neuropathologica CommunicationsPeer-reviewed·Feb 3, 2026
- Matrix remodeling plays an etiological role in driving laminin-α2 deficient pathology
Veronica Pini, Anthony Accorsi, … Mahasweta Girgenrath·bioRxiv·Jul 2, 2026
- Deregulation of multiple mechanisms shapes the onset of LAMA2-congenital muscular dystrophy
Susana G. Martins, Vanessa Ribeiro, … Sólveig Þorsteinsdóttir·Life Science AlliancePeer-reviewed·Oct 8, 2024
- Glycerolipid defects in skeletal muscle contribute to rhabdomyolysis in Tango2 deficiency
Jennifer G. Casey, Euri S Kim, … Vandana Gupta·bioRxiv·Nov 12, 2022